Yang et al. showed that ALDH3A1 is a key metabolic marker upregulated in pancreatic adenocarcinoma patients with new-onset diabetes, contributing to tumor progression, immune suppression, and poor prognosis [41]. Here, ALDH3A1 is linked to diabetes mellitus.